Related Experiment Videos
Neoadjuvant therapy in invasive bladder cancer. Problems and pitfalls
1Urologic Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
The Urologic Clinics of North America
|August 1, 1991
Summary
Some bladder tumors respond to combined therapy, but more research is needed. Randomized trials are essential to compare treatments and establish neoadjuvant therapy as standard for transitional-cell bladder cancer.
Area of Science:
- Uro-oncology
- Medical Oncology
- Clinical Research
Background:
- Transitional-cell tumors of the bladder represent a significant clinical challenge.
- Current treatment paradigms lack definitive comparative data for neoadjuvant therapy.
- The potential for chemotherapy in bladder cancer requires further investigation.
Purpose of the Study:
- To assess the efficacy of combined therapy in transitional-cell bladder tumors.
- To highlight the need for randomized controlled trials to evaluate treatment strategies.
- To explore novel chemotherapy agents and supportive therapies for bladder cancer.
Main Methods:
- Review of existing data on combined therapy for bladder cancer.
- Emphasis on the necessity of randomized controlled trials (RCTs).
- Discussion of potential research avenues including new chemotherapy agents and hematopoietic growth factors.
Main Results:
- Combined therapy shows promise in a subset of bladder tumors.
- Cisplatin-based chemotherapy demonstrates encouraging initial results in urothelial tumors.
- The study underscores the responsiveness of urothelial tumors to chemotherapy.
Conclusions:
- Randomized controlled trials are urgently needed to establish standard neoadjuvant therapy for bladder cancer.
- Further research into novel chemotherapy combinations and supportive care is warranted.
- Multidisciplinary collaboration is crucial for advancing bladder cancer treatment through integrated approaches.